Funding Announcements

Filter

Filter & sort

Keyword

Tag

Round

Sort by

Clear

The latest funding rounds from the UK tech ecosystem. Updated 31 July 2026.

Grant
£790K

The funding will support a consortium project developing open source software for the UK healthcare sector.

"We’re thrilled to have been given the opportunity by Innovate UK to prove that professional open source is the only viable solution to the NHS’s complex software needs. Innovate UK understood that we have ambitious aims to transform the NHS’s approach to digital technology, helping to create software that is the perfect clinical fit for today and adaptable for tomorrow saving lives and money simultaneously."
— Stuart Mackintosh, CEO
Grant
£1.0M

The company has obtained capital from the NHS England funded initiative to support pre-clinical development.

"After several years of research in collaboration with Mogrify, it is great to see our transdifferentiated cartilage cells gain commercial traction from grants such as the SBRI Healthcare and (pre-)clinical partners."
— Wael Kafienah, Director
Grant
£300K

The funding will support a joint project combining deep text mining and sparse data solutions.

"Adequate data curation underpins so much of the future success of research and development in science and Biorelate is continually investing in innovative ways to improve this. What really excites me about this project is the prospect of bringing two completely different, game-changing technologies together to achieve something entirely novel. We can’t wait to start!"
— Daniel Jamieson, CEO
Grant
£500K

The funding will support the implementation of specialised screening technology aimed at identifying rare diseases earlier in the patient journey.

"We are delighted to support Mendelian as part of our work into rare diseases. With over 3 million rare disease patients in the UK, innovative technologies using data analytics and machine learning like this are increasingly vital in ensuring that these conditions are diagnosed earlier to provide more targeted and personalised treatment for patients."
— Piers Ricketts, Chief Executive